Aurora (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) said on Monday that it has launched a new cannabis product to a German company, whose merchandise is sold in 25,000 pharmacies in Europe.
The new product “Cannabis Klenk” – produced in Canada – was launched after Aurora’s subsidiary Pedanios GmbH (“Pedanios”) signed an agreement with Heinrich Klenk GmbH & Co. KG (“Klenk”), one of Europe’s largest medicinal plant companies.
The product will be imported by Pedanios and distributed through Klenk’s wide-reaching pharmaceutical wholesale distribution network in Europe.
So far, “Cannabis Klenk” branded products are available at 20 distribution hubs in Germany to feed on demand and provide same-day delivery service to pharmacies where available.
While Klenk is known for its high-quality medicinal plant products, it is not clear if the newly launched product, which is cannabis-based, will be allowed to be sold in Europe, since medical marijuana is still not legal in many of its member states.
However, medical marijuana became legal in early 2017 in Germany.
According to the pharmaceutical publication Deutsche Apotheker Zeitung, the number of German patients receiving medical marijuana prescriptions has risen steadily since last year. Drug stores filled over 5,000 orders in the first four months of the year, with June booking some 2,213 prescriptions.
Before legalizing medical marijuana in Germany, an estimated 1,000 patients across the country had received special permission to use cannabis to treat their ailments.